MNI BRIEF: Fed's Bostic Says Bumpy Inflation Calls For Caution

CANADA NOV TRADE BALANCE -CAD323 MLN VS PRIOR -CAD544 MLN

MNI BRIEF: NGEU Potential Growth Lift Less Than Expected -ECB

MNI China Daily Summary: Tuesday, January 7

MNI China Press Digest Jan 7: CPI, New Loans, Local Bonds

MNI: PBOC Net Drains CNY150.6 Bln via OMO Tuesday

EZ/UK Bond Supply Calendar: IT Syndication; UK, DE Due Wed

EZ/UK Bond Supply Calendar: IT Syndication; UK, DE Due Wed

EZ/UK T-Bill Calendar: 3/6/12-Month EU-Bills Auction Wednesday

MNI EXCLUSIVE: EU-Mercosur Deal Close, But Likely Short-Lived - Officials

AUSTRALIA: 2025 Election Outcome Looking More Uncertain According To Newspoll

© 1982-2025 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Novo Nordisk (NOVOB: A1 Pos/AA-): Rare Disease Investment

HEALTHCARE
BulletCredit BulletsCEEMEADenmark

A reminder that 7% of sales are from rare diseases

  • Novo Nordisk today announced an DKK 8.5b ($1.2bn) new production facility to open in 2027.
  • The facility will concentrate on rare diseases such a haemophilia
  • Novoseven generates around DKK 7.7bn of annual sales (2.7%) and rare diseases in general account for 7% of revenue. New treatment Concizumab has been approved in the EU and Mim8 is at Phase III.
66 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

A reminder that 7% of sales are from rare diseases

  • Novo Nordisk today announced an DKK 8.5b ($1.2bn) new production facility to open in 2027.
  • The facility will concentrate on rare diseases such a haemophilia
  • Novoseven generates around DKK 7.7bn of annual sales (2.7%) and rare diseases in general account for 7% of revenue. New treatment Concizumab has been approved in the EU and Mim8 is at Phase III.